ペーター・シェンカー医師は、ゾーリンゲン医療センターの外科部長です。消化器腫瘍学および膵臓外科を専門としています。以前は、ドイツ初の認定大腸がんセンターで外科部長を務めていました。シェンカー医師は、ロボット手術や低侵襲手術に注力しています。バレット食道やクローン病などの複雑な疾患を治療しています。
ハサン・ムトル医師は、メディカルパーク・アンタルヤ病院コンプレックスの腫瘍内科医です。免疫療法、がんの標的療法、がん治療における遺伝子研究を専門としています。ムトル医師はハジェテペ大学で医学の学位を取得しました。医学教授の称号を保持しています。ムトル医師は、臓器腫瘍の診断と化学療法に注力しています。
イ・ソクグ教授は、ミョンジ病院の肝移植外科における第一人者です。これまでに約2,000例の肝移植手術を手がけました。韓国初の無輸血肝移植を成功させたほか、生後1ヶ月の乳児に対する肝細胞移植を実施しました。また、急性肝不全に対するバイオ人工肝臓の臨床使用を初めて主導しました。さらに、エジプトでの生体肝移植手術の執刀や、ベトナムの医療チームへの指導も行っています。
現在はミョンジ病院の外科学教授を務めており、サムスンソウル病院の臓器移植センター長を歴任しました。ソウル大学校で医学士および修士号を、カトリック大学校で医学博士号を取得しています。ボストン小児病院／ハーバード大学でフェローシップを修了し、ジョンズ・ホプキンス大学で移植研修を受けました。移植外科学および小児外科学の分野で3つの国内学会の会長を歴任しました。チョン・クンダン学術賞、ファイザー臨床医学賞、アステラス研究者賞など、数多くの受賞歴があります。447本の学術論文と13冊の著書（章担当）を発表しています。
ムスタファ・セルカン・アレムダル医師は、メディカルパーク・アンタルヤ病院コンプレックスの臨床腫瘍医です。複雑な固形腫瘍および血液がんの治療を専門としています。アレムダル医師は、アクデニズ大学で医学の学位を取得し、腫瘍学のフェローシップを修了しました。トルコ臨床腫瘍学会の活動的なメンバーです。
オメル・ブルチャク・ビニジエル医師は、イズミールのメディカルポイント国際病院の消化器内科医です。消化管がんの早期発見と炎症性腸疾患に注力しています。ビニジエル医師は韓国大学医学部で国際的なトレーニングを修了しました。手技およびロボット支援技術を用いて、肝臓、膵臓、消化器系の複雑な疾患を治療します。
セイムール・アスラノフ医師は、イズミルにあるメディカルポイント国際病院の消化器内科医です。エーゲ大学で専門研修を修了しました。アスラノフ医師は、炎症性腸疾患、肝疾患、消化器系がんの治療を行っています。イズミル医師会会員です。
セリン・カパン医師は、イスティニエ大学リブ病院トプカプ校の一般外科教授です。消化器外科および腹腔鏡下ヘルニア修復術を専門としています。カパン医師は、国際的な医学雑誌に50本以上の査読付き論文を発表しています。彼女の研究は、肛門周囲瘻および肝包虫症に焦点を当てています。
チョン・ウォンソク医師は、ナウン病院の消化器内科部長です。消化器疾患の治療を行っています。上部内視鏡検査、大腸内視鏡検査、ポリープ切除術、ESD（内視鏡的粘膜下層剥離術）を実施しています。胃がん、食道がん、ヘリコバクター・ピロリ感染症の管理を行っています。また、肝疾患やクローン病、潰瘍性大腸炎を含む炎症性腸疾患の治療も行っています。小腸カプセル内視鏡検査も提供しています。
認定：消化器内視鏡専門医。大韓消化器内視鏡学会終身会員。大韓内科学会正会員。
研修：慶熙大学校医学部。慶熙大学校医療センターでのインターンシップ。翰林大学聖心病院での内科レジデント。中央大学病院での消化器内科臨床フェローシップ。
ロペス・ジャマール医師は消化器画像診断のパイオニアであり、ルベル・インターナショナル病院の内視鏡ユニットを率いています。侵襲的な生検を行わずに肝臓の健康状態を評価するために、フィブロスキャンなどの高度な技術を使用しています。
ムハンメド・ムスタファ・アトチ医師は、Liv Hospital Topkapıの腫瘍内科准教授です。大腸がん、乳がん、胃がん、肺がんの治療を専門としています。以前は、ジェミル・タシュジオール教授記念市立病院で教育コーディネーターを務めていました。アトチ医師は、米国臨床腫瘍学会（ASCO）の会員です。
ヤサール・トゥナ医師は、メディカル・パーク・アンタルヤ病院コンプレックスの消化器内科医兼消化器外科医です。複雑な消化器疾患の治療と肥満外科手術を専門としています。トゥナ医師は、トルコ有数の臓器移植センターを擁する施設で手術を行っています。
サンチェス・ヤゲ医師は、スペインのキロンサルド・マルベーリャ病院の消化器内科医です。世界で初めて15mmのAXIOSステントを使用した専門家です。このデバイスは膵液貯留のドレナージに使用されます。スペインにおける内視鏡的粘膜下層剥離術の先駆者でもあります。また、アンダルシア地方にルーメンアポジションステントを用いた胃腸吻合術を導入しました。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Premkamol Patraithikul医師は、低侵襲手術の高度なトレーニングを受けた一般外科医です。Patraithikul医師はコンケーン大学で医学博士号を取得しました。タマサート大学で一般外科のレジデントを修了し、タイのマヒドン大学（シリラート病院）で腹腔鏡下手術のフェローシップを修了しました。
臨床専門分野には、腹腔鏡下手術およびロボット支援手術が含まれます。また、一般外科、肥満・体重管理手術、消化器疾患の手術も行っています。
パク・ジョンウォン教授は、肝細胞癌（HCC）治療において30年以上の経験を有する韓国の第一人者です。現在は明知病院の肝臓・肝がんセンターおよび統合がんケアセンターのセンター長を務めています。2003年には韓国初の肝細胞癌診療ガイドラインの策定を主導し、その後約20年にわたり改訂を統括してきました。同氏の研究チームは肝がんに対する陽子線治療の有効性を検証し、その成果は『Journal of Hepatology』に掲載されています。これまでにSCI収載論文を200報以上執筆。また、切除不能な肝細胞癌に対するニボルマブとイピリムマブの併用療法の有効性を示した2025年の「CheckMate 9DW」試験をはじめ、国際的な臨床試験のリーダーの一人としても貢献しています。
ソウル大学校医学博士（MD/PhD）、大韓民国医学翰林院正会員、元韓国肝癌学会会長、韓国肝細胞癌診療ガイドライン委員会委員長。国務総理表彰および保健福祉部長官表彰を受賞。ファイザー医学研究賞およびロシュ腫瘍学学術賞受賞。
ズルフ・セルトカヤ医師は、イスタンブールのAndro Expertiseの准教授であり、アンドロロジストです。欧州泌尿器科学会（EAU）のFEBU認定を取得しています。セルトカヤ医師は、男性の健康、性機能、および泌尿器科の美容処置に重点を置いています。自身のクリニックで患者を診察し、提携病院で手術を行っています。
ポートフォリオを見る
Yilmaz Bilgic医師は、イスタンブールのJCI認定病院であるMedipol Acibadem District Hospitalの消化器内科医です。クローン病、潰瘍性大腸炎、複雑な肝疾患の治療を専門としています。Bilgic医師は韓国のAnam病院で内視鏡の専門トレーニングを修了しました。また、ドイツのOlympusトレーニングセンターでERCPのトレーニングコースも修了しています。
ジェマレッティン・アイディン博士は、イスタンブールのメディポル・アジバデム地区病院の一般外科教授です。消化器外科と複雑な減量手術を専門としています。トルコ高等専門病院で消化器外科の権威あるフェローシップを修了しました。
医師は2012年から2016年までマルマラ大学医学部で放射線腫瘍学の専門研修を修了しました。それ以前には、2004年から2011年まで同大学で英語による医学の学士課程を修了しています。医師は、1998年から2004年までアゼルバイジャンのシルヴァン第16学校で受けた中等教育を皮切りに、強固な医学教育の基盤を持っています。